DEA Places Seizure Treatment Drug Into Schedule V
The Drug Enforcement Administration is placing the newly approved drug ganaxolone in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective June 1, ganaxolone, which was granted approval by the FDA in March, is…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until July 1.